HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
LSKB ANNOUNCES ENROLLMENT OF THE FIRST PATIENT IN ITS APATINIB-NIVOLUMAB COMBINATION STUDY
SALT LAKE CITY, USA, December 27, 2017 — LSK BioPharma (LSKB, Company) announced that it has enrolled the first patient in a clinical trial studying the combination of apatinib with the immuno-oncology drug nivolumab. This study (designated LSK-AM107) is an open-labeled, single-center, Phase 1 study designed to evaluate the safety, tolerability, and efficacy of adding apatinib to ongoing nivolumab treatment in patients with unresectable or metastatic cancer. The study is taking place at the Cancer Center of Southern California (CCSC) under the direction of Dr. Sant P. Chawla.
“I-O (immuno-oncology) has proven to be a promising tool in treating many cancers,” said Dr. Sung Chul Kim, President, “Based on preclinical studies, we believe that combining I-O with apatinib will make the therapy available to a wider population of cancer patients.”
LSKB is also planning to support an Investigator Initiated Trial (IIT) at a US institution studying the safety and efficacy of apatinib in combination with pembrolizumab. This study is expected to enroll its first patients in early 2018.